Dr. Larson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2020 Santa Monica Blvd., Suite 600
Santa Monica, CA 90404Phone+1 310-829-5471Fax+1 310-829-5471
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2013
University of ChicagoFellowship, Hematology and Medical Oncology, 2010 - 2011- University of ChicagoResidency, Internal Medicine, 2007 - 2010
University of Minnesota Medical SchoolClass of 2007
Certifications & Licensure
CA State Medical License 2011 - 2025
IL State Medical License 2007 - 2011- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Stem Cell Gene Therapy for Sickle Cell Disease Start of enrollment: 2014 Dec 01
Publications & Presentations
PubMed
- 173 citationsPembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson
The Lancet. Haematology. 2019-07-18 - 162 citationsPembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialSaad Z. Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo
The Lancet. Haematology. 2019-09-01 - 26 citationsMotixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.Zachary D Crees, Michael P Rettig, Reyka G Jayasinghe, Keith Stockerl-Goldstein, Sarah M Larson
Nature Medicine. 2023-04-01
Press Mentions
UCLA and Parker Institute Continue Collaboration to Advance Next-Generation Cancer ImmunotherapiesOctober 16th, 2024- New CAR T Approach Minimizes Resistance, Helps Avoid Relapse in Non-Hodgkin's B-cell LymphomaApril 10th, 2021
UCLA Opens Pioneering CAR T Clinical Trial Aimed at Extending the Lives of People Diagnosed with the Most Common Types of Lymphoma and LeukemiaOctober 16th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
